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Abstract.7
Background: Protein misfolding disorders are frequently implicated in neurodegenerative conditions. Familial Alzheimer’s
disease (fAD) is an early-onset and aggressive form of Alzheimer’s disease (AD), driven through autosomal dominant
mutations in genes encoding the amyloid precursor protein and presenilins 1 and 2. The incidence of epilepsy is higher in AD
patients with shared neuropathological hallmarks in both disease states, including the formation of neurofibrillary tangles.
Similarly, in Parkinson’s disease, dementia onset is known to follow neurofibrillary tangle deposition.
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Objective: Human exposure to aluminum has been linked to the etiology of neurodegenerative conditions and recent studies
have demonstrated a high level of co-localization between amyloid- and aluminum in fAD. In contrast, in a donor exposed
to high levels of aluminum later developing late-onset epilepsy, aluminum and neurofibrillary tangles were found to deposit
independently. Herein, we sought to identify aluminum and neurofibrillary tangles in fAD, Parkinson’s disease, and epilepsy
donors.
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Methods: Aluminum-specific fluorescence microscopy was used to identify aluminum in neurofibrillary tangles in human
brain tissue.
18
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Results: We observed aluminum and neurofibrillary-like tangles in identical cells in all respective disease states. Co-deposition
varied across brain regions, with aluminum and neurofibrillary tangles depositing in different cellular locations of the same cell.
20
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Conclusion: Neurofibrillary tangle deposition closely follows cognitive-decline, and in epilepsy, tau phosphorylation asso-
ciates with increased mossy fiber sprouting and seizure onset. Therefore, the presence of aluminum in these cells may
exacerbate the accumulation and misfolding of amyloidogenic proteins including hyperphosphorylated tau in fAD, epilepsy,
and Parkinson’s disease.
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Keywords: -synuclein, aluminum in human brain tissue, amyloid-, epilepsy, familial Alzheimer’s disease, Parkinson’s
disease, tau
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INTRODUCTION28
Familial Alzheimer’s disease (fAD) is differenti-29
ated from the sporadic form of the disease by its30
early age of onset, typically occurring before the31
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age of 65. This rare hereditary condition represents 32
less than 5% of individuals, who go on to develop 33
Alzheimer’s disease (AD) [1]. Mutations in genes 34
encoding the amyloid precursor protein (APP), prese- 35
nilin 1 (PSEN1), and presenilin 2 (PSEN2), mark the 36
autosomal dominant pattern of fAD inheritance [2, 3]. 37
Subsequently, the enhanced proteolytic processing of 38
amyloid- protein precursor (APP) through sequen- 39
tial cleavage by -secretase (B-site APP-cleaving 40
enzyme 1, BACE1) and -secretase, drives the 41
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formation of the pathogenic amyloid- (A) pep-42
tides [4]. Histological analysis of postmortem fAD43
brain tissue is principally characterized by the44
extracellular deposition of A in senile plaques,45
intracellular neurofibrillary tangles (NFTs) of hyper-46
phosphorylated tau protein, and cerebral amyloid47
angiopathy (CAA) [5].48
As the second most common form of neurodegen-49
erative disorder after AD, Parkinson’s disease (PD)50
shares protein misfolding abnormalities including tau51
and A proteinopathies [6, 7]. The deposition of52
NFTs and senile plaques have been found in the53
brains of donors with PD, in comparable quantities54
and regions to those observed in AD [6]. Autoso-55
mal dominant mutations of the SNCA gene in PD are56
known to trigger disease-causing missense mutations57
of the -synuclein protein, normally responsible for58
pre-synaptic signaling and membrane trafficking [8].59
Subsequent molecular changes in -synuclein cause60
the protein to misfold and deposit as Lewy bodies61
in neuronal somata and Lewy neurites in neuronal62
cell processes. Consequently, the concomitant loss63
of dopaminergic neurons in the substantia nigra pars64
compacta in the midbrain directly follows PD patho-65
genesis, as characterized by Braak staging of Lewy66
pathology [6, 7, 9]. Neuropathological forms of -67
synuclein and tau are rarely found in isolation and68
their co-deposition with other amyloidogenic pro-69
teins including A, have been associated with AD-70
like co-morbidities in vivo [10]. Those pathological71
conformations adopted, promote the cross-seeding72
of -synuclein and tau. Further templating and pro-73
tein aggregation may then occur through a prion-like74
transmission mechanism, promoting disease spread75
between adjacent neurons. Taken collectively, such76
has highlighted a synergistic role for tauopathies in77
accelerating aberrant -synuclein inclusions and vice78
versa in PD brain tissues [6, 7, 10].79
Aluminum is the third most abundant element and80
the most abundant metal in the Earth’s crust. Despite81
its ubiquity, aluminum is non-essential to life, partici-82
pates in biochemical reactions, and accumulates over83
time in the central nervous system (CNS) [11, 12].84
Aluminum is known to accumulate in human brain85
tissue of donors diagnosed with both neurodegen-86
erative and neurodevelopmental disorders including87
AD [13, 14], PD [15, 16], and epilepsy [17]. Inves-88
tigations into the distribution of aluminum in human89
brain tissue of donors diagnosed with fAD have90
revealed co-deposition of the metal ion in senile91
plaques [13, 14]. In a Colombian cohort of fAD92
donors presenting with a PSEN1-E280A mutation,93
aluminum was also identified in CAA-laden blood 94
vessels, in which its co-localization with fibrillar 95
A was observed [14]. Donors with this mutation 96
exhibit increased levels of cortical A and early- 97
onset and aggressive AD etiology [18]. Owing to 98
the unique association of aluminum with A and the 99
high levels of aluminum found within these brain tis- 100
sues relative to controls [19], such implicated a role 101
for the metal in the neuropathology of fAD [14]. 102
Elevated levels of aluminum have been reported in 103
neuromelanin-containing neurons and in Lewy bod- 104
ies of the substantia nigra region of PD donors [15, 105
16]. In addition, densely packed and phosphorylated 106
neurofilaments of alpha-synuclein in Lewy bodies 107
and neurites would be expected to bind aluminum 108
with high affinity, thereby promoting its intracellular 109
accumulation [7, 10, 15]. Furthermore, in the pres- 110
ence of aluminum, the rate of -synuclein fibrillation 111
has been shown to increase in vitro, inducing con- 112
formational changes of the protein to an aggregated 113
insoluble form [20]. 114
While the co-deposition of aluminum with A has 115
been suggested in fAD, such an association has yet 116
to be confirmed with intraneuronal NFTs of hyper- 117
phosphorylated tau protein [13, 14]. In renal dialysis 118
patients, elevated aluminum concentrations and its 119
subsequent accumulation in brain tissue was asso- 120
ciated with increased insoluble hyperphosphorylated 121
tau and depleted normal tau protein in the cerebral 122
cortex [21]. Owing to the high affinity of aluminum 123
for phosphate groups, both adenosine triphosphate 124
(ATP) and DNA are known to act as ligands for chela- 125
tion of aluminum in intraneuronal pools [22, 23]. 126
Therefore, the high number of inorganic phosphate 127
ligands on intraneuronal tau protein in NFTs would 128
be predicted in the cerebral cortex of both fAD and 129
PD patients [10]. 130
To assess such an association of aluminum with 131
NFTs in vivo, we have made use of aluminum-specific 132
fluorescence microscopy, utilizing the fluorophore 133
lumogallion (4-chloro-3-(2,4-dihydroxyphenylazo)- 134
2-hydroxybenzene-1-sulphonic acid). As a selective 135
fluorescent molecular probe for the detection of intra- 136
cellular aluminum in vivo, we have optimized its 137
use for the detection of potential intraneuronal alu- 138
minum in Colombian PSEN1-E280A fAD, PD, and 139
epilepsy donors [13, 14]. Herein, we have made use of 140
thioflavin S as a fluorophore for the detection of NFTs 141
of hyperphosphorylated tau protein. ThS is frequently 142
used for the identification of NFTs in human brain 143
tissue [7, 14, 17, 24, 25]. When stained with ThS, 144
NFTs most notably produce characteristic flame-like 145
U
nc
or
re
ct
ed
 A
ut
ho
r P
ro
of
M.J. Mold et al. / Aluminum and Tau in Neurological Disorders 3
morphologies in intraneuronal occlusions, distinctive146
from larger extracellular senile plaques that typically147
span tens of microns in diameter [26].148
Previously, we have demonstrated the intracellular149
accumulation of aluminum in glial cells and neuronal150
debris in a case of epilepsy, brought on by aluminum151
poisoning in the individual’s potable water supply152
[17]. While extensive NFT deposition was noted in153
the frontal, parietal, occipital, and temporal lobes,154
no direct association with aluminum was identified155
[17]. A recent study of temporal lobe epilepsy (TLE)156
patients who underwent temporal lobe resection,157
demonstrated striking similarities with post-mortem158
temporal lobe specimens from AD patients [27].159
Therein, increased phosphorylation of pathological160
tau was noted in NFTs in both TLE and AD tissues161
[27]. Therefore, we have additionally investigated162
potential similarities in the intraneuronal accumula-163
tion of aluminum and NFTs in a case study of an164
individual exposed to high levels of aluminum, that165
later died of asphyxiation through an epileptic fit [17].166
Finally, we show preliminary data for aluminum and167
NFT-like deposition in PD, allowing for comparisons168
of their distribution in human brain tissue to be drawn169
across complex neurological disease states.170
METHODS171
Human brain tissue172
Formalin-fixed paraffin-embedded (FFPE) brain173
tissue blocks tissue from Colombian fAD donors car-174
rying a PSEN1-E280A mutation were obtained from175
the Universidad de Antioquia, Medellin, Colombia176
brain tissue bank, following ethical approval by Keele177
University, UK (ERP 2391) [14]. FFPE brain tissue178
blocks from a 60-year-old male donor who died as a179
consequence of asphyxiation following an epileptic180
fit were provided by University Hospitals Plymouth,181
NHS Trust, UK and sent to Keele University upon182
request of the coroner to investigate the content and183
distribution of aluminum. The deceased as described184
by the coroner, was a victim of the Lowermoor Treat-185
ment Works, Camelford, who in 1988 was exposed to186
high levels of aluminum in his potable water supply.187
Full details of the pathology of this case are described188
elsewhere [17]. PD brain tissue from an 87-year-old189
male donor was received as 5 m adjacent serial sec-190
tions on electrostatically-charged glass slides from191
Parkinson’s UK Brain Bank at Imperial College Lon-192
don, funded by Parkinson’s UK (NREC approval no.193
18/WA/0238).194
Microtomy 195
All chemicals were from Sigma Aldrich, UK 196
unless otherwise stated. Brain tissue received as 197
FFPE tissue blocks were cooled on wet ice for 198
10 min and adjacent serial sections prepared at 199
5 m using a rotary RM2025 microtome, equipped 200
with Surgipath DB80 LX low-profile stainless-steel 201
microtome blades (both from Leica Microsystems, 202
UK). Sections were floated onto ultrapure water (con- 203
ductivity <0.067 S/cm) at 40◦C and transferred onto 204
SuperFrost® Plus adhesion slides (Thermo Scientific, 205
UK). Excess wax was removed from dried sections 206
by heating at 62◦C for 20 min, before dewaxing and 207
rehydration procedures. 208
Dewaxing and rehydration of tissue sections 209
All brain tissue sections were dewaxed with Histo- 210
Clear (National Diagnostics, US) for 3 min, fresh 211
Histo-Clear for 1 min and transferred into 100% v/v 212
ethanol (HPLC grade used throughout) for 2 min 213
to remove the clearing agent. Sections were subse- 214
quently rehydrated using an ethanol gradient from 215
95, 70, 50, and 30% v/v for 1 min in each solvent, 216
before rehydration in ultrapure water for 35 s. 217
Lumogallion staining 218
All staining procedures were performed at 219
ambient temperature, away from light. Rehy- 220
drated fAD tissue sections were fully immersed in 221
Coplin jars containing 1 mM lumogallion (4-chlo 222
ro-3-(2,4-dihydroxyphenylazo)-2-hydroxybenzene- 223
1-sulphonic acid, TCI Europe N. V., Belgium) in 224
50mM PIPES pH 7.4 for 6 h. Autofluorescence 225
controls were prepared by incubating sections in 226
the buffer only. Epilepsy brain tissue sections were 227
stained for 24 h in Coplin jars and PD sections 228
for 45 min in humidity chambers, in the presence 229
of the fluorophore or the buffer only for autofluo- 230
rescence controls. Following staining, all sections 231
were rinsed in the same PIPES buffer and washed 232
for 30 s in ultrapure water, before mounting with 233
Fluoromount™ under glass coverslips. 234
Thioflavin s staining 235
Following analysis of lumogallion stained sections 236
via fluorescence microscopy, mounted sections on 237
glass slides were placed in ultrapure water with gen- 238
tle agitation provided by a stirrer bar, overnight. Once 239
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coverslips had lifted, lumogallion stained sections240
were outlined with a hydrophobic PAP pen, allowing241
for re-staining with thioflavin S (ThS) in humidity242
chambers. Sections were re-stained with ca 0.075%243
w/v ThS in 50% v/v ethanol for 8 min. Following244
ThS staining, slides were twice rinsed for 10 s in245
fresh 80% v/v ethanol and washed for 30 s in ultra-246
pure water. Sections were subsequently mounted with247
Fluromount™ using new glass coverslips.248
Microscopy249
Sections were analyzed by use of an Olympus250
BX50 fluorescence microscope (mercury source)251
equipped with a BX-FLA reflected light attachment252
and vertical illuminator. Lumogallion fluorescence253
was acquired using a U-MNIB3 filter cube (bandpass254
λex: 470–495 nm, dichromatic mirror: 505 nm, long-255
pass λem: 510 nm) and ThS fluorescence by use of a256
U-MWBV2 filter cube (bandpass λex: 400–440 nm,257
dichromatic mirror: 455 nm, longpass λem: 475 nm,258
both from Olympus, UK). Images were captured259
using a ColorView III CCD camera using the CellD260
software suite (Olympus, SiS Imaging Solutions,261
GmbH). Light transmission values and exposure262
settings were fixed across respective treatments.263
Merging of fluorescence channels was performed264
using Photoshop (Adobe Systems Inc., US).265
RESULTS266
Aluminum and neurofibrillary tangle deposition267
in familial Alzheimer’s disease268
To identify the potential deposition of aluminum269
and NFTs in fAD, sections were first stained270
with lumogallion and deposits of aluminum iden-271
tified. Aluminum-specific fluorescence microscopy272
identified extracellular aluminum deposition in the273
temporal cortex of a 45-year-old female Colombian274
fAD donor (Fig. 1A). Higher magnifications revealed275
the presence of nearby neuronal cells loaded with276
punctate cytosolic deposits of the metal ion, via an277
intense orange fluorescence emission.278
Numerous and frequently intraneuronal lipo-279
fuscin deposits were readily differentiated from280
lumogallion-reactive aluminum, by a weaker green/281
yellow fluorescence emission (see Supplementary282
Fig. 1). Upon re-staining of the section with ThS, the283
identical lumogallion-reactive neuron stained posi-284
tively for intraneuronal NFTs at its periphery, via a285
green fluorescence emission (Fig. 1B). Merging of 286
the fluorescence channels revealed that aluminum and 287
NFTs were located in the same cell (Fig. 1C), with 288
the brightfield overlay confirming their intracellular 289
deposition (Fig. 1D). 290
Similarly, intraneuronal aluminum appearing as 291
punctate orange deposits were found in the parietal 292
cortex of a 60-year-old male Colombian fAD donor 293
(Fig. 2A). Such was differentiated from a green 294
autofluorescence emission of the non-stained serial 295
section (see Supplementary Fig. 2). The identical 296
neuron revealed intracellular ThS-reactive NFTs, 297
as highlighted by a green fluorescence emission 298
(Fig. 2B). Interestingly, merging of the fluores- 299
cence channels identified the co-localization of 300
lumogallion-reactive aluminum and ThS-reactive 301
NFTs at the periphery of the cell (Fig. 2C). Overlay- 302
ing of the brightfield channel revealed both deposits 303
to be enclosed by a clear cell membrane, confirming 304
their intracellular co-deposition (Fig. 2D). 305
Herein, prolonged staining with lumogallion iden- 306
tified the presence of intracellular aluminum in the 307
parietal cortex of a 57-year-old female Colombian 308
fAD donor (Fig. 3A), versus a weak green autofluo- 309
rescence emission of the non-stained serial section 310
(see Supplementary Fig. 3). Microglial cells and 311
neurons near cellular debris stained positively for 312
aluminum (Fig. 3A) and ThS-reactive senile plaques 313
(Fig. 3B) were observed. While aluminum appeared 314
to be distributed in cell soma, ThS-reactive neuropil- 315
like threads were highlighted via a green fluorescence 316
emission in dendritic/axonal-like cell projections, 317
upon merging of fluorescence (Fig. 3C) and bright- 318
field (Fig. 3D) channels. 319
Aluminum and neurofibrillary tangle deposition 320
in epilepsy 321
To draw comparisons between aluminum and NFT 322
distribution in fAD and epilepsy, brain tissue from a 323
60-year old male donor who died as a consequence of 324
an epileptic fit was sequentially stained with lumogal- 325
lion and ThS. Prolonged staining with lumogallion 326
revealed the presence of intracellular aluminum in 327
neuronal cells in the temporal cortex, via an orange 328
fluorescence emission (Fig. 4A). Analysis of the 329
non-stained serial section revealed a green autofluo- 330
rescence emission of brain parenchyma with punctate 331
yellow intraneuronal deposits being confirmed in the 332
same cells (Fig. 4B). ThS counter-staining of the 333
identical lumogallion-stained section demonstrated 334
the presence of NFT-like deposits in axons and 335
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Fig. 1. Intracellular aluminum co-located with ThS-reactive NFTs in the temporal cortex of a Colombian donor (Case 90: Female, aged 45)
with fAD (PSEN1-E280A mutation). A) Punctate intracellular aluminum (orange, white arrows) in neuronal cells exhibiting positive (green)
fluorescence for (B) intraneuronal NFTs (black arrows) with (C) merging of fluorescence channels and the brightfield overlay (D) depicting
their co-deposition. Magnified inserts are denoted by asterisks in the respective fluorescence micrographs. Al, aluminum; ThS, thioflavin S.
Magnification: X 400, scale bars: 50 m.
dendrites of the same neuron, via a green fluores-336
cence emission (Fig. 4C). Merging of fluorescence337
and brightfield channels confirmed the intraneuronal338
distribution of aluminum and axonal-like deposition339
of NFTs, in the same cell (Fig. 4D).340
Aluminum and neurofibrillary tangle deposition341
in Parkinson’s disease342
To draw comparisons to NFT and aluminum depo-343
sition in fAD and epilepsy, conventional lumogallion344
and ThS counter-staining were performed on donor345
tissues obtained from an 87-year-old male with PD346
[13, 17, 28]. Lumogallion staining revealed positive347
orange fluorescence of aluminum in tangle-like for-348
mations, in epithelial cells lining the choroid plexus of349
the hippocampus (Fig. 5A). Green autofluorescence350
and occasional lipofuscin deposition were noted in351
the same cells, in the non-stained adjacent serial352
section (Fig. 5B). ThS counter-staining identified353
Biondi ring-like tangles via an intensive green flu- 354
orescence emission, reminiscent of NFTs in the 355
identical epithelial cells (Fig. 5C). Merging of the flu- 356
orescence and brightfield channels identified promi- 357
nent aluminum deposition, co-located with Biondi 358
ring-like tangles in the same epithelial cell (Fig. 5D). 359
DISCUSSION 360
We have demonstrated the presence of intracellular 361
aluminum and NFTs in neurons in the cerebral cortex 362
of both fAD and epilepsy donors and co-located with 363
Biondi ring-like tangles in epithelial cells lining the 364
choroid plexus in PD. In fAD, intracellular punctate 365
deposits of aluminum were observed in neurons in the 366
parietal and temporal cortex of three individual fAD 367
donors, all carrying the PSEN1-E280A mutation. 368
ThS-reactive NFTs were found in the identical neu- 369
rons, upon counter-staining. Interestingly, the pattern 370
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Fig. 2. Intracellular aluminum co-located with ThS-reactive NFTs in the parietal cortex of a Colombian donor (Case 218: Male, aged 60)
with fAD (PSEN1-E280A mutation). A) Punctate intracellular aluminum (orange, white arrows) in neuronal cells exhibiting positive (green)
fluorescence for (B) intraneuronal NFTs (black arrows) with (C) merging of fluorescence channels and the brightfield overlay (D) depicting
their co-localization. Magnified inserts are denoted by asterisks in the respective fluorescence micrographs. Al, aluminum; ThS, thioflavin
S. Magnification: X 400, scale bars: 50 m.
of aluminum and NFT co-deposition was seen to vary371
in cortical neurons, with each depositing in different372
cellular locations. Typically, flame-like NFTs were373
observed at the periphery of neurons, with aluminum374
appearing to be deposited in cell nuclei. In fAD,375
only a single incidence of diffuse aluminum stain-376
ing and potentially co-located intraneuronal NFTs377
were observed in the parietal cortex. Intracellular alu-378
minum was also observed in microglial-like cells near379
ThS-reactive senile plaques, in the same donor.380
Senile plaque morphologies and neuritic dystro-381
phy have been shown to revert upon the activation382
of microglial cells in the 5xFAD murine model of383
AD [29]. Microglia are known to play a pivotal role384
in their ability to block aberrant tangle formation,385
though their high loading with aluminum observed386
in our study may prevent their ability to do so in vivo387
[14, 30, 31]. It is important to stress that while alu-388
minum and NFTs were observed in the same cortical389
neurons, aluminum was predominantly observed to390
be co-located with ThS-reactive senile plaques, as 391
has been previously reported in the same Colombian 392
donor cohort [14]. Furthermore, several NFTs stained 393
positively with ThS without producing any signal for 394
aluminum upon prolonged lumogallion staining. 395
In the brain tissue of a donor with late-onset 396
adult epilepsy, aluminum and NFTs were both found 397
deposited in cortical neurons of the temporal lobe. We 398
observed that while aluminum was generally found 399
deposited in the nucleus, ThS-reactive NFTs were 400
observed in axonal-like projections in the same neu- 401
ron. Our previous report of aluminum distribution in 402
the brain tissue of this donor, only identified alu- 403
minum in glial cell populations, thereby depositing 404
at sites away from intraneuronal NFTs of hyperphos- 405
phorylated tau protein [17]. 406
In a donor with PD, Biondi ring-like tangles 407
were found in epithelial cells, lining the choroid 408
plexus of the hippocampus. Those tangles identi- 409
fied were both lumogallion and ThS-reactive and 410
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Fig. 3. Intracellular aluminum in glia and neurons co-located with ThS-reactive NFTs and amyloid- in the parietal cortex of a Colombian
donor (Case 260: Female, aged 57) with fAD (PSEN1-E280A mutation). A) Punctate intracellular aluminum (orange) in a microglial cell
(white arrow). B) Intraneuronal NFTs (green, black arrows) with (C) merging of fluorescence channels depicting their co-deposition. D)
The brightfield overlay depicts cell membranes. Magnified inserts are denoted by asterisks in the respective fluorescence micrographs. Al,
aluminum; ThS, thioflavin S. Magnification: X 400, scale bars: 50 m.
thereby demonstrated the presence of aluminum411
within these fibrillar inclusions. We have previously412
made the observations of aluminum in epithelial cells413
of the choroid plexus in a donor with CAA and414
ThS-reactive Biondi ring-like tangles in the same415
donor with epilepsy; revisited in this study [17, 32].416
Interestingly, both were victims of the now infa-417
mous Camelford aluminum poisoning incident and418
herein we report the first co-localization of these neu-419
ropathological hallmarks, within the same epithelial420
cells in PD.421
Biondi ring tangles were originally thought to422
be artefacts described as “off-target” bi ding of the423
flortaucipir-based PET radioligand, [F-18]AV-1451424
[33]. However, in a follow-up study by Ikonomovic425
and colleagues, immunolabelling of the choroid426
plexus of aged AD brains revealed the presence of427
phosphorylated tau with minimal immunoreactivity428
for A [34]. Those tangles identified, were described429
as Biondi ring tangles that have been previously430
reported in aged healthy and AD brain tissues 431
[34–36]. A continuing research effort is currently 432
underway to better characterize PET tracers for 433
tau imaging and the reasons underlying off-target 434
labelling in living patients. However, these studies 435
have continued to report the presence of tau in 436
Biondi ring tangles, supporting our preliminary 437
observations of these neuropathological hallmarks 438
in a donor with PD [37, 38]. 439
The blood-cerebrospinal fluid barrier has been 440
suggested to act as a potential entry route of - 441
synuclein into the brain through its passage across 442
choroid plexus epithelia via energy-dependent active 443
transport [39]. Therefore, the presence of aluminum 444
in these cells may exacerbate the accumulation 445
and misfolding of amyloidogenic proteins including 446
hyperphosphorylated tau and -synuclein. Indeed, 447
tau and -synuclein can interact in cells and their 448
aberrant cross-seeding has been suggested to syn- 449
ergistically enhance protein misfolding and fibrillar 450
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Fig. 4. Intracellular aluminum co-located with ThS-reactive NFTs in neurons in the temporal cortex of a 60-year-old male donor with
epilepsy. A) Intranuclear aluminum (orange, white arrows) and (B) autofluorescence of the non-stained section. C) The identical neuronal
cell exhibiting positive (green) fluorescence for NFTs (black arrows) with (D) merging of fluorescence channels depicting their co-localization.
Magnified inserts are denoted by asterisks in the respective fluorescence micrographs of which merging of the brightfield overlay is depicted
in the lower panels. Al, aluminum; ThS, thioflavin S. Magnification: X 400, scale bars: 50 m.
inclusions in vivo [7, 10]. In addition, PD-specific451
mutations including those in leucine-rich repeat452
kinase 2 (LRRK2), has been implicated in the hyper-453
phosphorylation of tau and the subsequent deposition454
of NFTs [6, 40].455
The intranuclear deposition of aluminum has been456
highlighted in the past, likely owing to the high affin-457
ity of aluminum binding to the phosphate backbone458
of DNA [41, 42]. We have previously reported the459
unequivocal presence of intranuclear aluminum in460
vitro in human spermatozoa and frequently in vivo,461
in the brain of donors with autism spectrum disor-462
der, multiple sclerosis, epilepsy, and fAD [14, 17,463
28, 43, 44]. While previous studies of fAD brain464
tissues revealed only occasional aluminum deposits465
in cortical neurons, pro-longed staining with the466
lumogallion fluorophore, herein, demonstrated an467
intense positive signal for the metal ion above back-468
ground fluorescence. As aluminum readily binds469
to negatively charged phosphate moieties and also470
forms strong 1:1 complexes with lumogallion, such471
competitive binding equilibria may have shifted in472
favor of forming a fluorescent complex [23]. In473
this manner, Al3+(aq) ions removed from nuclear474
DNA, may have allowed sufficient complexation with 475
lumogallion to produce a positive intranuclear metal 476
signal [45–47]. 477
Aluminum is known to bind to the microtubule- 478
associated protein tau and especially upon its 479
hyperphosphorylation forming aberrant insoluble 480
NFTs [48]. Intraneuronal NFTs are frequently 481
observed in the cerebral cortex of fAD, PD, and 482
epilepsy patients, collectively prompting our study 483
to probe their intracellular presence [7, 14, 17, 484
27]. Epilepsy occurrence is more frequent in AD 485
patients [49]. Concomitant with increased tau phos- 486
phorylation, increased mossy fiber sprouting has also 487
been demonstrated in pentylenetetrazole-kindled rat 488
models of epilepsy [50]. Furthermore, detailed his- 489
tological analyses of human brain tissue excised 490
from drug-resistant temporal lobe epilepsy (TLE) 491
donors, have revealed intraneuronal tau phosphory- 492
lation, bearing striking similarities to those found in 493
AD temporal lobe tissues [27]. Increased brain A 494
deposition has been suggested to be enhanced in the 495
presence of aluminum, through its acceleration of 496
proteolytic processing of APP via the amyloido- 497
genic pathway [51]. Subsequently, the formation of 498
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Fig. 5. Intracellular aluminum co-located with ThS-reactive Biondi ring-like tangles in the choroid plexus (hippocampus) of an 87-year-old
male donor with Parkinson’s disease. A) Intracellular aluminum (orange, white arrows) in epithelial cells lining the choroid plexus and
(B) autofluorescence of the non-stained section. C) The identical epithelial cell exhibiting positive (green) fluorescence for Biondi ring
tangles (black arrows) with (D) merging of fluorescence channels depicting their co-localization. Magnified inserts are denoted by asterisks
in the respective fluorescence micrographs of which merging of the brightfield overlay is depicted in the lower panels. Al, aluminum; ThS,
thioflavin S. Magnification: X 400, scale bars: 50 m.
A fibrils is known to induce phosphorylation of tau499
in both in vivo and in vitro models of AD [52, 53].500
While further research is needed to establish a501
role for aluminum in the catalysis of A and sub-502
sequent NFT deposition in fAD, PD and epilepsy,503
our results now demonstrate the co-existence of alu-504
minum in these neuropathological hallmarks [14]. We505
have used ThS for the detection of NFTs in fAD and506
epilepsy brain tissues and similarly unveiled the pres-507
ence of Biondi ring tangles in PD. A limitation of our508
study is the sole use of ThS for this purpose, which509
is also known to bind to and visualize senile plaques510
of A [54]. Kinetic-based studies monitoring fibril-511
lation of the -synuclein protein, have also shown512
reactivity to benzothiazole-based dyes, upon the for-513
mation of -pleated sheet structures [7, 20]. Owing514
to the large size of extracellularly deposited senile515
plaques, these could be differentiated from smaller516
intracellular fibrillar morphologies and flame-like517
NFTs, herein observed in fAD and epilepsy brain518
tissues. Likewise, we could also identify charac-519
teristic Biondi ring tangles in the choroid plexus520
of a donor with PD that have frequently produced521
positive immunoreactivity against phosphorylated 522
tau in previous studies [33–38]. Future research 523
identifying specific phosphorylated tau residues and 524
immunoreactivity against A and -synuclein is a 525
logical next step to delineate aluminum accumula- 526
tion in specific fibrillar assemblies. We now aim to 527
perform immunolabelling against these specific neu- 528
ropathological targets to shed light upon the role of 529
aluminum in their mechanistic processes of assembly, 530
in vivo. 531
Donors from the Colombian PSEN1-E280A fAD 532
cohort are known to develop tauopathies later in 533
life, as has been demonstrated by positron emis- 534
sion tomography (PET), in living patients [55]. 535
Therein and similarly in PD, hyperphosphorylation 536
of tau depositing as NFTs follows senile plaque 537
deposition, before symptom onset and concurrent 538
cognitive decline [7, 10, 56]. Future investigations of 539
aluminum, A, and NFT deposition in neurodegener- 540
ative and neurodevelopmental disorders would help 541
to shed light upon the potentially shared patholog- 542
ical mechanisms underlying these complex disease 543
states. 544
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[9] Braak H, Tredici KD, Rüb U, de Vos RAI, Steur ENHJ, 598
Braak E (2003) Staging of brain pathology related to spo- 599
radic Parkinson’s disease. Neurobiol Aging 24, 197-211. 600
[10] Yan X, Uronen RL, Huttunen HJ (2020) The interaction of 601
-synuclein and tau: A molecular conspiracy in neurode- 602
generation? Semin Cell Dev Biol 99, 55-64. 603
[11] Exley C, Mold M (2019) Aluminium in human brain tissue: 604
How much is too much? J Biol Inorg Chem 24, 1279-1282. 605
[12] Exley C, Mold M (2020) Imaging of aluminium and amyloid 606
 in neurodegenerative disease. Heliyon 6, e03839. 607
[13] Mirza A, King A, Troakes C, Exley C (2017) Aluminium in 608
brain tissue in familial Alzheimer’s disease. J Trace Elem 609
Med Bio 40, 30-36. 610
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